6533b871fe1ef96bd12d24cd
RESEARCH PRODUCT
Mobilization of endothelial progenitor cells in acute cardiovascular events in the PROCELL study: Time-course after acute myocardial infarction and stroke
Juan SanchisJaume RoquerJosé T. Ortiz-pérezGines EscolarGemma G. GenéCarlos Bueno-betíCarlos EhermenegildoXavier FreixaJulio NúñezMercè RoquéCarole JungMaribel Diaz-ricartIsaac SubiranaSusana NovellaMagda HerasMiguel A. ValverdeElisa Cuadrado-godiaAnna OliverasJaume MarrugatAnder Regueirosubject
AdultMaleVascular Endothelial Growth Factor ACD31medicine.medical_specialtyTime FactorsMyocardial InfarctionCD34Vascular Cell Adhesion Molecule-1Cell CountInflammationSeverity of Illness IndexEndothelial progenitor cellImmunophenotypingchemistry.chemical_compoundVasculogenesisRisk FactorsInternal medicinevon Willebrand FactormedicineHumansProspective StudiesProgenitor cellMolecular BiologyCells CulturedAgedEndothelial Progenitor Cellsbusiness.industryEndothelial CellsMiddle AgedStrokeVascular endothelial growth factorPhenotypeEndocrinologychemistryCase-Control StudiesCardiologyCD146Femalemedicine.symptomCardiology and Cardiovascular MedicinebusinessFollow-Up Studiesdescription
The mobilization pattern and functionality of endothelial progenitor cells after an acute ischemic event remain largely unknown. The aim of our study was to characterize and compare the short- and long-term mobilization of endothelial progenitor cells and circulating endothelial cells after acute myocardial infarction or atherothrombotic stroke, and to determine the relationship between these cell counts and plasma concentrations of vascular cell adhesion molecule (VCAM-1) and Von Willebrand factor (VWF) as surrogate markers of endothelial damage and inflammation. In addition, we assessed whether endothelial progenitor cells behave like functional endothelial cells. We included 150 patients with acute myocardial infarction or atherothrombotic stroke and 145 controls. Endothelial progenitor cells [CD45-, CD34+, KDR+, CD133+], circulating endothelial cells [CD45-, CD146+, CD31+], VWF, and VCAM-1 levels were measured in controls (baseline only) and in patients within 24h (baseline) and at 7, 30, and 180 days after the event. Myocardial infarction patients had higher counts of endothelial progenitor cells and circulating endothelial cells than the controls (201.0/mL vs. 57.0/mL; p<0.01 and 181.0/mL vs. 62.0/mL; p<0.01). Endothelial progenitor cells peaked at 30 days post-infarction (201.0/mL vs. 369.5/mL; p<0.01), as did VCAM-1 (573.7 ng/mL vs. 701.8 ng/mL; p<0.01). At 180 days post-infarction, circulating endothelial cells and VWF decreased, compared to baseline. In stroke patients, the number of endothelial progenitor cells - but not circulating endothelial cells - was higher than in controls (90.0/mL vs. 37.0/mL; p=0.01; 105.0/mL vs. 71.0/mL; p=0.11). At 30 days after stroke, however, VCAM-1 peaked (628.1/mL vs. 869.1/mL; p<0.01) but there was no significant change in endothelial progenitor cells (90/mL vs. 78/mL; p<0.34). At 180 days after stroke, circulating endothelial cells and VWF decreased, compared to baseline. Cultured endothelial progenitor cells from controls and myocardial infarction patients had endothelial phenotype characteristics and exhibited functional differences in adhesion and Ca(2+) influx, but not in proliferation and vasculogenesis. In myocardial infarction patients, VCAM-1 levels and mobilization of endothelial progenitor cells peaked at 30 days after the ischemic event. Although a similar VCAM-1 kinetic was observed in stroke patients, endothelial progenitor cells did not increase. Endothelial progenitor cells had mature endothelial capabilities in vitro.
year | journal | country | edition | language |
---|---|---|---|---|
2015-03-01 | Journal of Molecular and Cellular Cardiology |